RBM5 Knockout cell line (ACHN)

Gene knockout cell lines are generated using CRISPR-Cas9 based technology to precisely disrupt target genes, enabling functional genomics research, disease modeling, and target validation.

RBM5 (RNA binding motif protein 5) encodes a nuclear RNA-binding protein that functions as a component of the spliceosome and participates in pre-mRNA processing. RBM5 contributes to regulation of cell-cycle arrest and apoptosis through alternative processing of multiple target transcripts, including those associated with p53 signaling. It is therefore relevant to studies of RNA splicing, cell-cycle regulation, apoptosis, and tumor-associated cellular processes.

Initiated in November 1979, ACHN is a well-established human cell line derived from the malignant pleural effusion of a 22-year-old Caucasian male with widely metastatic renal adenocarcinoma. The cells were originally seeded directly into culture flasks in Eagle’s MEM supplemented with 10% FBS, and maintained through passages for 150 days before being inoculated subcutaneously into nude mice, where they formed palpable, locally invasive tumors within four weeks. Notably, both the parental ACHN cells and those recovered from the nude mouse tumors are distinctly growth-inhibited by human interferons, making ACHN a premier in vitro and in vivo model platform for investigating renal oncology progression, cytokine responses, and preclinical drug evaluation.

Comprehensive quality control includes STR authentication, sterility testing (bacteria and fungi), and mycoplasma screening to ensure purity and performance. Genotype is confirmed by two rounds of PCR and Sanger sequencing, and complete validation reports are provided for make-to-order products.